Research into neuroblastoma
Results from this phase 2 trial showed that bevacizumab with temozolomide and irinotecan may help treat children with refractory and relapsed neuroblastoma.
This page summarizes ongoing research in neuroblastoma, covering diagnostic imaging, molecular profiling, and various therapeutic modalities including chemotherapy, targeted agents (Lorlatinib, bevacizumab), immunotherapies (anti‑GD2 T‑cells, nivolumab, dinutuximab‑beta), novel radiotherapy techniques (IMAT, proton beam therapy), and novel metabolic drugs (BCT‑100). It highlights several clinical trials and Phase 2 studies aimed at improving outcomes for high‑risk pediatric patients.
Neuroblastoma is a life‑threatening childhood cancer; advances in targeted and immunologic therapies could markedly improve survival and reduce long‑term morbidity.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study